Symbols / IART Stock $10.57 +2.42% Integra LifeSciences Holdings Corporation

Healthcare • Medical Devices • United States • NMS
IART (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Ms. Mojdeh Poul
Exch · Country NMS · United States
Market Cap 823.80M
Enterprise Value 2.59B
Income -516.47M
Sales 1.64B
FCF (ttm) 44.46M
Book/sh 13.40
Cash/sh 3.38
Employees 4,427
Insider 10d —
IPO Aug 16, 1995
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 4.13
PEG 0.67
P/S 0.50
P/B 0.79
P/C —
EV/EBITDA 8.71
EV/Sales 1.59
Quick Ratio 1.19
Current Ratio 2.54
Debt/Eq 195.01
LT Debt/Eq —
EPS (ttm) -6.74
EPS next Y 2.56
EPS Growth —
Revenue Growth -1.70%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-05
Earnings (prior) 2026-02-26
ROA 2.39%
ROE -39.90%
ROIC —
Gross Margin 56.22%
Oper. Margin 12.44%
Profit Margin -31.58%
Shs Outstand 77.94M
Shs Float 58.96M
Insider Own 14.38%
Instit Own 97.81%
Short Float 16.19%
Short Ratio 11.86
Short Interest 9.16M
52W High 17.54
vs 52W High -39.74%
52W Low 8.70
vs 52W Low 21.49%
Beta 1.06
Impl. Vol. 25.00%
Rel Volume 0.76
Avg Volume 812.00K
Volume 616.27K
Target (mean) $15.43
Tgt Median $12.00
Tgt Low $9.00
Tgt High $25.00
# Analysts 7
Recom Hold
Prev Close $10.32
Price $10.57
Change 2.42%
About

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products. Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$15.43
Mean price target
2. Current target
$10.57
Latest analyst target
3. DCF / Fair value
$10.27
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$10.57
Low
$9.00
High
$25.00
Mean
$15.43

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-15 main Truist Securities Hold → Hold $12
2026-04-15 down Argus Research Buy → Hold —
2026-03-11 main Citigroup Sell → Sell $9
2026-02-27 main Wells Fargo Equal-Weight → Equal-Weight $12
2025-11-03 reit Truist Securities Hold → Hold $13
2025-10-31 main Citigroup Sell → Sell $11
2025-10-31 main JP Morgan Underweight → Underweight $13
2025-10-15 main Truist Securities Hold → Hold $15
2025-10-07 main Citigroup Sell → Sell $12
2025-05-09 main JMP Securities Market Outperform → Market Outperform $25
2025-05-06 main JP Morgan Underweight → Underweight $12
2025-05-06 main Wells Fargo Equal-Weight → Equal-Weight $13
2025-04-11 main Truist Securities Hold → Hold $19
2025-03-31 up Argus Research Hold → Buy —
2025-02-26 reit Citizens Capital Markets Market Outperform → Market Outperform $35
2024-11-05 main Citigroup Sell → Sell $22
2024-10-14 main Truist Securities Hold → Hold $21
2024-10-07 main B of A Securities Underperform → Underperform $18
2024-10-07 up BTIG Sell → Neutral —
2024-10-01 main Citigroup Sell → Sell $16
News
RSS: Latest IART news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-11 SINGH HARVINDER Officer — 20,138 — —
2026-01-06 POUL MOJDEH Chief Executive Officer — 1,390 — —
2025-11-05 GRAVES JEFFREY A. Director — 9,000 $11.35 $102,150
2025-10-10 SINGH HARVINDER Officer — 11,965 — —
2025-05-09 BRADLEY KEITH Director — 19,592 $0.00 $0
2025-05-09 CLAY SHAUNDRA Director — 19,592 $0.00 $0
2025-05-09 LO RENEE WONLAI Director — 19,592 $0.00 $0
2025-05-09 GRAVES JEFFREY A. Director — 19,592 $0.00 $0
2025-05-09 ESSIG STUART M Officer and Director — 31,837 $0.00 $0
2025-05-09 HILL BARBARA BENTON Director — 26,531 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
1,635.24
+1.53%
1,610.53
+4.47%
1,541.57
-1.03%
1,557.67
Operating Revenue
1,635.24
+1.53%
1,610.53
+4.47%
1,541.57
-1.03%
1,557.67
Cost Of Revenue
803.62
+10.32%
728.47
+10.90%
656.84
+11.83%
587.36
Reconciled Cost Of Revenue
666.75
+9.51%
608.86
+11.57%
545.70
+13.00%
482.94
Gross Profit
831.62
-5.72%
882.06
-0.30%
884.74
-8.82%
970.31
Operating Expense
813.62
-4.69%
853.65
+10.40%
773.21
+5.72%
731.39
Research And Development
98.97
-14.22%
115.38
+10.73%
104.19
+2.96%
101.19
Selling General And Administration
699.70
-2.41%
716.98
+9.19%
656.64
+6.54%
616.32
Total Expenses
1,617.25
+2.22%
1,582.12
+10.63%
1,430.05
+8.44%
1,318.75
Operating Income
18.00
-36.66%
28.41
-74.53%
111.53
-53.32%
238.92
Total Operating Income As Reported
-493.37
-1836.55%
28.41
-74.53%
111.53
-53.32%
238.92
EBITDA
-325.42
-268.36%
193.29
-24.48%
255.96
-32.96%
381.79
Normalized EBITDA
185.95
-3.80%
193.29
-24.48%
255.96
-32.84%
381.14
Reconciled Depreciation
151.83
+7.76%
140.89
+14.07%
123.51
+4.41%
118.30
EBIT
-477.25
-1010.86%
52.40
-60.44%
132.45
-49.73%
263.49
Total Unusual Items
-511.37
0.00
0.00
-100.00%
0.64
Total Unusual Items Excluding Goodwill
-511.37
0.00
0.00
-100.00%
0.64
Special Income Charges
-511.37
0.00
0.00
-100.00%
0.64
Impairment Of Capital Assets
511.37
0.00
0.00
—
Net Income
-516.47
-7337.70%
-6.94
-110.25%
67.74
-62.48%
180.55
Pretax Income
-563.50
-2989.88%
-18.24
-122.50%
81.07
-62.10%
213.89
Net Non Operating Interest Income Expense
-67.78
-33.98%
-50.59
-48.04%
-34.17
+9.29%
-37.68
Interest Expense Non Operating
86.25
+22.12%
70.63
+37.48%
51.38
+3.60%
49.59
Net Interest Income
-67.78
-33.98%
-50.59
-48.04%
-34.17
+9.29%
-37.68
Interest Expense
86.25
+22.12%
70.63
+37.48%
51.38
+3.60%
49.59
Interest Income Non Operating
18.47
-7.81%
20.04
+16.50%
17.20
+44.35%
11.92
Interest Income
18.47
-7.81%
20.04
+16.50%
17.20
+44.35%
11.92
Other Income Expense
-513.72
-13125.25%
3.94
+6.08%
3.72
-70.61%
12.65
Other Non Operating Income Expenses
-2.35
-159.61%
3.94
+6.08%
3.72
-69.03%
12.01
Gain On Sale Of Business
—
0.00
0.00
-100.00%
0.64
Tax Provision
-47.03
-316.43%
-11.29
-184.73%
13.33
-60.03%
33.34
Tax Rate For Calcs
0.00
-60.48%
0.00
+28.05%
0.00
+5.13%
0.00
Tax Effect Of Unusual Items
-42.44
0.00
0.00
-100.00%
0.10
Net Income Including Noncontrolling Interests
-516.47
-7337.70%
-6.94
-110.25%
67.74
-62.48%
180.55
Net Income From Continuing Operation Net Minority Interest
-516.47
-7337.70%
-6.94
-110.25%
67.74
-62.48%
180.55
Net Income From Continuing And Discontinued Operation
-516.47
-7337.70%
-6.94
-110.25%
67.74
-62.48%
180.55
Net Income Continuous Operations
-516.47
-7337.70%
-6.94
-110.25%
67.74
-62.48%
180.55
Normalized Income
-47.55
-584.80%
-6.94
-110.25%
67.74
-62.37%
180.01
Net Income Common Stockholders
-516.47
-7337.70%
-6.94
-110.25%
67.74
-62.48%
180.55
Diluted EPS
-6.74
-7388.89%
-0.09
-110.71%
0.84
-61.11%
2.16
Basic EPS
-6.74
-7389.72%
-0.09
-110.38%
0.87
-59.88%
2.16
Basic Average Shares
76.67
-0.64%
77.16
-1.29%
78.17
-6.48%
83.59
Diluted Average Shares
76.67
-0.64%
77.16
-3.95%
80.34
-3.89%
83.59
Diluted NI Availto Com Stockholders
-516.47
-7337.70%
-6.94
-110.25%
67.74
-62.48%
180.55
Amortization
14.95
-29.76%
21.29
+72.03%
12.38
-10.85%
13.88
Amortization Of Intangibles Income Statement
14.95
-29.76%
21.29
+72.03%
12.38
-10.85%
13.88
Depreciation Amortization Depletion Income Statement
14.95
-29.76%
21.29
+72.03%
12.38
-10.85%
13.88
Depreciation And Amortization In Income Statement
14.95
-29.76%
21.29
+72.03%
12.38
-10.85%
13.88
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
3,602.00
-10.78%
4,037.42
+6.75%
3,781.99
-2.77%
3,889.76
Current Assets
1,159.54
+7.20%
1,081.68
+2.23%
1,058.04
-8.91%
1,161.50
Cash Cash Equivalents And Short Term Investments
263.74
-3.59%
273.57
-11.49%
309.10
-32.31%
456.66
Cash And Cash Equivalents
235.05
-4.60%
246.38
-10.86%
276.40
-39.47%
456.66
Other Short Term Investments
28.69
+5.52%
27.19
-16.83%
32.69
0.00
Receivables
278.85
+2.38%
272.37
+5.03%
259.33
-1.57%
263.46
Accounts Receivable
278.85
+2.38%
272.37
+5.03%
259.33
-1.57%
263.46
Gross Accounts Receivable
286.08
+2.43%
279.29
+5.71%
264.21
-1.33%
267.77
Allowance For Doubtful Accounts Receivable
-7.23
-4.53%
-6.92
-41.77%
-4.88
-13.36%
-4.30
Inventory
492.74
+14.83%
429.09
+10.13%
389.61
+20.03%
324.58
Raw Materials
130.77
+3.84%
125.94
+5.68%
119.17
+45.51%
81.90
Work In Process
99.35
+25.09%
79.42
+7.28%
74.03
+4.87%
70.60
Finished Goods
262.61
+17.38%
223.73
+13.91%
196.40
+14.13%
172.09
Prepaid Assets
96.09
+24.79%
77.00
+14.31%
67.36
-21.45%
85.76
Assets Held For Sale Current
—
—
—
—
Other Current Assets
28.13
-5.14%
29.65
-9.16%
32.64
+5.19%
31.03
Total Non Current Assets
2,442.46
-17.37%
2,955.74
+8.51%
2,723.95
-0.16%
2,728.26
Net PPE
584.90
+6.39%
549.76
+10.75%
496.38
+8.01%
459.59
Gross PPE
1,028.85
+8.68%
946.69
+9.59%
863.83
+9.44%
789.32
Accumulated Depreciation
-443.95
-11.85%
-396.92
-8.02%
-367.45
-11.44%
-329.73
Properties
0.00
0.00
0.00
0.00
Land And Improvements
4.16
+336.55%
0.95
-2.66%
0.98
+1.24%
0.97
Buildings And Improvements
78.31
+296.54%
19.75
+32.90%
14.86
+1.01%
14.71
Machinery Furniture Equipment
444.97
+9.76%
405.41
+5.72%
383.47
+8.22%
354.35
Construction In Progress
179.61
-8.65%
196.63
+43.24%
137.28
+32.15%
103.88
Other Properties
140.57
-2.41%
144.04
-7.77%
156.18
+2.70%
152.08
Leases
181.24
+0.74%
179.90
+5.17%
171.06
+4.73%
163.34
Goodwill And Other Intangible Assets
1,749.82
-24.07%
2,304.54
+8.54%
2,123.30
-1.95%
2,165.49
Goodwill
615.16
-43.92%
1,096.95
+3.93%
1,055.46
+1.60%
1,038.88
Other Intangible Assets
1,134.66
-6.04%
1,207.59
+13.09%
1,067.83
-5.22%
1,126.61
Non Current Deferred Assets
69.85
+100.02%
34.92
-24.21%
46.08
+0.19%
45.99
Non Current Deferred Taxes Assets
69.85
+100.02%
34.92
-24.21%
46.08
+0.19%
45.99
Other Non Current Assets
37.88
-43.05%
66.52
+14.30%
58.19
+1.76%
57.19
Total Liabilities Net Minority Interest
2,558.54
+2.66%
2,492.14
+13.58%
2,194.10
+5.21%
2,085.36
Current Liabilities
455.98
-50.55%
922.13
+200.39%
306.98
-4.34%
320.91
Payables And Accrued Expenses
229.87
+12.46%
204.41
+5.82%
193.17
+6.06%
182.13
Payables
99.38
+20.45%
82.50
-10.64%
92.33
-9.57%
102.10
Accounts Payable
95.73
+16.03%
82.50
-10.64%
92.33
-9.57%
102.10
Current Accrued Expenses
130.49
+7.04%
121.91
+20.89%
100.84
+26.00%
80.03
Pensionand Other Post Retirement Benefit Plans Current
74.08
-13.48%
85.62
+13.47%
75.45
-4.21%
78.77
Total Tax Payable
3.65
0.00
—
—
Income Tax Payable
3.65
0.00
—
—
Current Debt And Capital Lease Obligation
140.57
-77.39%
621.62
+1984.91%
29.82
-43.48%
52.75
Current Debt
126.55
-79.15%
607.08
+4077.80%
14.53
-61.89%
38.12
Other Current Borrowings
126.55
-79.15%
607.08
+4077.80%
14.53
-61.89%
38.12
Current Capital Lease Obligation
14.02
-3.58%
14.54
-4.87%
15.28
+4.51%
14.62
Current Deferred Liabilities
11.46
+9.35%
10.48
+22.75%
8.54
+17.74%
7.25
Current Deferred Revenue
11.46
+9.35%
10.48
+22.75%
8.54
+17.74%
7.25
Total Non Current Liabilities Net Minority Interest
2,102.56
+33.92%
1,570.02
-16.80%
1,887.12
+6.95%
1,764.45
Long Term Debt And Capital Lease Obligation
1,892.62
+38.86%
1,362.95
-17.49%
1,651.87
+5.71%
1,562.61
Long Term Debt
1,729.56
+44.61%
1,196.02
-19.46%
1,485.02
+5.68%
1,405.19
Long Term Capital Lease Obligation
163.06
-2.32%
166.93
+0.05%
166.85
+5.99%
157.42
Non Current Deferred Liabilities
5.66
-90.69%
60.83
+72.25%
35.32
-44.24%
63.34
Non Current Deferred Taxes Liabilities
5.66
-90.69%
60.83
+72.25%
35.32
-44.24%
63.34
Other Non Current Liabilities
204.28
+39.69%
146.24
-26.86%
199.94
+44.36%
138.50
Stockholders Equity
1,043.46
-32.47%
1,545.28
-2.68%
1,587.88
-12.00%
1,804.40
Common Stock Equity
1,043.46
-32.47%
1,545.28
-2.68%
1,587.88
-12.00%
1,804.40
Capital Stock
0.92
+0.76%
0.92
+0.77%
0.91
+0.44%
0.91
Common Stock
0.92
+0.76%
0.92
+0.77%
0.91
+0.44%
0.91
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
92.29
+0.74%
91.61
+0.76%
90.92
+0.49%
90.48
Ordinary Shares Number
77.89
+0.94%
77.16
-1.29%
78.17
-6.56%
83.65
Treasury Shares Number
14.40
-0.32%
14.45
+13.29%
12.75
+86.88%
6.82
Additional Paid In Capital
1,338.39
+1.13%
1,323.43
+1.61%
1,302.48
+2.00%
1,276.98
Retained Earnings
423.44
-54.95%
939.91
-0.73%
946.86
+7.71%
879.12
Gains Losses Not Affecting Retained Earnings
-30.08
-9.09%
-27.57
-82.52%
-15.11
-247.16%
10.27
Treasury Stock
689.21
-0.32%
691.41
+6.82%
647.26
+78.38%
362.86
Other Equity Adjustments
-30.08
-9.09%
-27.57
-82.52%
-15.11
-247.16%
10.27
Total Equity Gross Minority Interest
1,043.46
-32.47%
1,545.28
-2.68%
1,587.88
-12.00%
1,804.40
Total Capitalization
2,773.02
+1.16%
2,741.30
-10.79%
3,072.90
-4.26%
3,209.59
Working Capital
703.56
+340.95%
159.56
-78.76%
751.06
-10.65%
840.59
Invested Capital
2,899.57
-13.40%
3,348.37
+8.45%
3,087.43
-4.94%
3,247.72
Total Debt
2,033.18
+2.45%
1,984.56
+18.01%
1,681.68
+4.11%
1,615.36
Net Debt
1,621.06
+4.13%
1,556.72
+27.27%
1,223.15
+23.97%
986.65
Capital Lease Obligations
177.08
-2.42%
181.47
-0.36%
182.13
+5.86%
172.04
Net Tangible Assets
-706.36
+6.97%
-759.26
-41.81%
-535.41
-48.28%
-361.09
Tangible Book Value
-706.36
+6.97%
-759.26
-41.81%
-535.41
-48.28%
-361.09
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
50.38
-61.06%
129.38
-7.55%
139.96
-47.08%
264.47
Cash Flow From Continuing Operating Activities
50.38
-61.06%
129.38
-7.55%
139.96
-47.08%
264.47
Net Income From Continuing Operations
-516.47
-7337.70%
-6.94
-110.25%
67.74
-62.48%
180.55
Depreciation Amortization Depletion
151.83
+7.76%
140.89
+14.07%
123.51
+4.41%
118.30
Depreciation And Amortization
151.83
+7.76%
140.89
+14.07%
123.51
+4.41%
118.30
Other Non Cash Items
-15.41
-269.57%
9.09
-57.21%
21.24
+299.58%
-10.64
Stock Based Compensation
18.58
-23.77%
24.38
+21.02%
20.14
-27.35%
27.73
Asset Impairment Charge
511.37
+4088.43%
12.21
0.00
0.00
Deferred Tax
-66.26
-219.64%
-20.73
-74.43%
-11.88
-159.21%
-4.58
Deferred Income Tax
-66.26
-219.64%
-20.73
-74.43%
-11.88
-159.21%
-4.58
Operating Gains Losses
0.49
-67.25%
1.50
+92.54%
0.78
+110.42%
-7.46
Gain Loss On Sale Of PPE
0.49
-67.25%
1.50
+92.54%
0.78
+111.40%
-6.81
Change In Working Capital
-33.74
-8.80%
-31.01
+61.99%
-81.57
-106.94%
-39.42
Change In Receivables
-0.48
-106.56%
7.40
+61.07%
4.59
+113.55%
-33.91
Changes In Account Receivables
-0.48
-106.56%
7.40
+61.07%
4.59
+113.55%
-33.91
Change In Inventory
-46.76
-66.12%
-28.15
+52.91%
-59.77
-105.24%
-29.12
Change In Prepaid Assets
-2.80
+65.78%
-8.19
-408.71%
2.65
-69.21%
8.61
Change In Payables And Accrued Expense
26.72
+1099.40%
-2.67
+86.78%
-20.23
-216.64%
17.34
Change In Payable
26.72
+1099.40%
-2.67
+86.78%
-20.23
-216.64%
17.34
Change In Account Payable
26.72
+1099.40%
-2.67
+86.78%
-20.23
-216.64%
17.34
Change In Other Working Capital
3.40
-3.95%
3.54
+2665.63%
0.13
-97.01%
4.27
Change In Other Current Assets
3.34
+217.63%
-2.84
+66.70%
-8.54
-291.15%
-2.18
Change In Other Current Liabilities
-17.16
-18347.31%
-0.09
+77.32%
-0.41
+90.76%
-4.44
Investing Cash Flow
-108.06
+72.35%
-390.81
-314.97%
-94.18
-60.77%
-58.58
Cash Flow From Continuing Investing Activities
-108.06
+72.35%
-390.81
-314.97%
-94.18
-60.77%
-58.58
Net PPE Purchase And Sale
-81.44
+22.01%
-104.42
-56.16%
-66.86
-114.32%
-31.20
Purchase Of PPE
-81.44
+22.01%
-104.42
-56.16%
-66.86
-57.91%
-42.34
Sale Of PPE
—
0.00
0.00
-100.00%
11.14
Capital Expenditure
-95.64
+16.38%
-114.37
-71.05%
-66.86
-42.01%
-47.09
Net Investment Purchase And Sale
-12.43
-1004.29%
1.37
+105.03%
-27.31
-656.39%
4.91
Purchase Of Investment
-19.43
+63.44%
-53.13
-62.49%
-32.69
0.00
Sale Of Investment
7.00
-87.16%
54.50
+912.82%
5.38
+9.61%
4.91
Net Business Purchase And Sale
0.00
+100.00%
-277.81
0.00
+100.00%
-27.55
Purchase Of Business
0.00
+100.00%
-277.81
0.00
+100.00%
-51.51
Gain Loss On Sale Of Business
—
0.00
0.00
+100.00%
-0.64
Net Intangibles Purchase And Sale
-14.20
-42.69%
-9.95
0.00
+100.00%
-4.74
Purchase Of Intangibles
-14.20
-42.69%
-9.95
0.00
+100.00%
-4.74
Financing Cash Flow
28.34
-88.09%
237.86
+203.45%
-229.93
+8.74%
-251.95
Cash Flow From Continuing Financing Activities
28.34
-88.09%
237.86
+203.45%
-229.93
+8.74%
-251.95
Net Issuance Payments Of Debt
50.81
-83.03%
299.37
+449.30%
54.50
+150.56%
-107.80
Issuance Of Debt
720.70
+48.14%
486.50
+194.67%
165.10
+305.15%
40.75
Repayment Of Debt
-669.89
-257.98%
-187.13
-69.20%
-110.60
+25.55%
-148.55
Long Term Debt Issuance
720.70
+48.14%
486.50
+194.67%
165.10
+305.15%
40.75
Long Term Debt Payments
-669.89
-257.98%
-187.13
-69.20%
-110.60
+25.55%
-148.55
Net Long Term Debt Issuance
50.81
-83.03%
299.37
+449.30%
54.50
+150.56%
-107.80
Net Common Stock Issuance
-0.22
+99.58%
-52.47
+80.92%
-275.00
-120.00%
-125.00
Common Stock Payments
-0.22
+99.58%
-52.47
+80.92%
-275.00
-120.00%
-125.00
Repurchase Of Capital Stock
-0.22
+99.58%
-52.47
+80.92%
-275.00
-120.00%
-125.00
Proceeds From Stock Option Exercised
0.96
-85.04%
6.40
+48.20%
4.32
-21.01%
5.46
Net Other Financing Charges
-23.21
-50.40%
-15.43
-12.31%
-13.74
+44.18%
-24.62
Changes In Cash
-29.34
-24.53%
-23.56
+87.20%
-184.15
-299.77%
-46.06
Effect Of Exchange Rate Changes
18.02
+378.73%
-6.46
-266.21%
3.89
+136.27%
-10.72
Beginning Cash Position
246.38
-10.86%
276.40
-39.47%
456.66
-11.06%
513.45
End Cash Position
235.05
-4.60%
246.38
-10.86%
276.40
-39.47%
456.66
Free Cash Flow
-45.25
-401.47%
15.01
-79.46%
73.09
-66.38%
217.38
Interest Paid Supplemental Data
—
64.40
+45.37%
44.30
+4.98%
42.20
Income Tax Paid Supplemental Data
—
22.70
-3.81%
23.60
-34.26%
35.90
Sale Of Business
—
0.00
0.00
-100.00%
23.96
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category